Glaukos has announced the approval by the United States Food and Drug Administration (FDA) of iDose TR, a travoprost intracameral implant to treat glaucoma.

Glaukos said iDose TR is a first-ofits-kind, long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time.

It is intended to improve the standard of care by addressing the patient non-compliance issues and chronic side effects associated with topical glaucoma medications.

FDA approval was based on robust Phase 3 clinical program consisting of two pivotal studies that randomised 1,150 subjects across 89 clinical sites, Glaukos said in a news release.1

“We now have a new tool that will confront the standard legacy practice of relying on topical drops, which are known to cause uncomfortable side effects and present a myriad of challenges,” said Dr John Berdahl, clinician and researcher at Vance Thompson Vision.

Reference avaialable at mivision.com.au